TE1 Stock Chart & Stats
€62.38
€0.18(0.28%)
At close: 4:00 PM EDT
€62.38
€0.18(0.28%)
Day’s Range― - ―
52-Week Range€36.26 - €64.90
Previous CloseN/A
Volume0.00
Average Volume (3M)46.00
Market Cap
€10.19B
Enterprise Value€11.12B
Total Cash (Recent Filing)€264.71M
Total Debt (Recent Filing)€289.09M
Price to Earnings (P/E)62.0
Beta0.71
Next Earnings
Nov 03, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding156,818,240
10 Day Avg. Volume4
30 Day Avg. Volume46
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)5.23
Price to Sales (P/S)9.07
P/FCF Ratio41.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€64.95Price Target Upside4.12% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)1.81
Revenue Forecast (FY)€1.13B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Platform RevenueBio-Techne’s recurring reagent purchases and instrument consumable pull-through can create durable customer relationships and repeat revenue. This model benefits from ongoing experimentation and clinical workflows, while proprietary platforms such as RNAscope and ProteinSimple can deepen adoption over multiple quarters.
High Gross Margins And Revenue ExpansionStrong gross margins indicate differentiated products and meaningful value in Bio-Techne’s research and diagnostic portfolio. The 2026 revenue acceleration provides evidence of renewed commercial momentum, supporting reinvestment in innovation, sales coverage, and expanding life-science applications.
Merck Acquisition Approval And Strategic ScaleShareholder approval and expiration of the U.S. antitrust waiting period materially advance the planned Merck transaction. If remaining conditions are satisfied, Bio-Techne would gain access to Merck’s global scale and complementary life-science capabilities, potentially strengthening distribution and workflow reach.
Bears Say
Volatile ProfitabilityThe sharp change in net margin shows that Bio-Techne’s earnings power has not been consistently stable, even though gross margins remain strong. Such variability can complicate planning, reduce confidence in normalized profitability, and limit the predictability of returns over the next several quarters.
Uneven Free-cash-flow MomentumBio-Techne converts earnings into cash effectively, yet the sharp 2026 decline in free-cash-flow growth indicates uneven cash generation momentum. Continued volatility could constrain the timing of internal investment, acquisitions, or other capital-allocation initiatives despite a generally healthy cash base.
Merger Completion Remains ConditionalAlthough the merger has cleared important milestones, remaining regulatory approvals and customary closing conditions leave execution risk unresolved. A delayed or unsuccessful closing could prolong strategic uncertainty, disrupt operating priorities, and prevent Bio-Techne from realizing the expected benefits of Merck ownership.
TE1 FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was €36.26 and its highest was €64.90 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is €10.19B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Nov 03, 2026 which is in 20 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Aug 12, 2026. The company reported €0.466 earnings per share for the quarter, beating the consensus estimate of €0.465 by <€0.001.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne does not currently pay dividends.
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.4.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 156,818,240 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of €0.466 in its last earnings report, beating expectations of €0.465. Following the earnings report the stock price went up 0.257%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in DE:TE1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Techne Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€64.95 (4.12% Upside)
€64.95 (4.12% Upside)
Blogger Sentiment
Neutral
DE:TE1 Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.39%
12-Months-Change
Fundamentals
Return on Equity
8.90%
Trailing 12-Months
Asset Growth
4.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
TE1 Net revenue Breakdown
71.98% Protein Sciences
27.68% Diagnostics and Genomics
-0.11% Intersegment
0.45% Other revenue

TE1 Stock 12 Month Forecast
Average Price Target
€64.95
▲(4.12% Upside)
Technical Analysis
Adaptive Biotechnologies
―
Maravai Lifesciences Holdings
―
AbCellera Biologics
―
AbSci
―
Kailera Therapeutics, Inc.
―








